PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Cancer Research and Treatment10.4143/crt.2018.2262019512510-518Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular CarcinomaChanghoon Yoo, Jihoon Kang, Ho Yeong Lim, Jee Hyun Kim, Myung-Ah Lee, Kyung-Hun Lee, Tae-You Kim, Baek-Yeol Ryoohttp://e-crt.org/upload/pdf/crt-2018-226.pdf, http://e-crt.org/journal/view.php?doi=10.4143/crt.2018.226, http://www.e-crt.org/upload/pdf/crt-2018-226.pdf
The Oncologist10.1634/theoncologist.2017-03252018236658A First‐in‐Human Phase I Study of OPB‐111077, a Small‐Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced CancersAnthony Tolcher, Keith Flaherty, Geoffrey I. Shapiro, Jordan Berlin, Thomas Witzig, Thomas Habermann, Andrea Bullock, Edwin Rock, Agnes Elekes, Chester Lin, Dusan Kostic, Naoto Ohi, Drew Rasco, Kyriakos P. Papadopoulos, Amita Patnaik, Lon Smith, Gregory M. Cotehttps://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.2017-0325, https://onlinelibrary.wiley.com/doi/full-xml/10.1634/theoncologist.2017-0325, https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.2017-0325
Hepatology Research10.1111/hepr.12504201545131283-1291Phase 1 and pharmacological trial of OPB-31121, a signal transducer and activator of transcription-3 inhibitor, in patients with advanced hepatocellular carcinomaTakuji Okusaka, Hideki Ueno, Masafumi Ikeda, Shuichi Mitsunaga, Masato Ozaka, Hiroshi Ishii, Osamu Yokosuka, Yoshihiko Ooka, Ryo Yoshimoto, Yasuo Yanagihara, Kiwamu Okitahttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fhepr.12504, http://onlinelibrary.wiley.com/wol1/doi/10.1111/hepr.12504/fullpdf
Cancer Chemotherapy and Pharmacology10.1007/s00280-014-2480-22014741125-130Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumorsJohanna C. Bendell, David S. Hong, Howard A. Burris, Aung Naing, Suzanne F. Jones, Gerald Falchook, Patricia Bricmont, Agnes Elekes, Edwin P. Rock, Razelle Kurzrockhttp://link.springer.com/content/pdf/10.1007/s00280-014-2480-2.pdf, http://link.springer.com/article/10.1007/s00280-014-2480-2/fulltext.html, http://link.springer.com/content/pdf/10.1007/s00280-014-2480-2, http://link.springer.com/content/pdf/10.1007/s00280-014-2480-2.pdf
Cancer Research and Treatment10.4143/crt.2014.2492015474607-615Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid TumorsDo-Youn Oh, Se-Hoon Lee, Sae-Won Han, Mi-Jung Kim, Tae-Min Kim, Tae-You Kim, Dae Seog Heo, Miyuki Yuasa, Yasuo Yanagihara, Yung-Jue Banghttp://e-crt.org/upload/pdf/crt-2014-249.pdf, http://e-crt.org/journal/view.php?doi=10.4143/crt.2014.249, http://www.e-crt.org/upload/pdf/crt-2014-249.pdf
Therapeutic Advances in Medical Oncology10.1177/1758835920913426202012175883592091342Erratum to A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinomahttp://journals.sagepub.com/doi/pdf/10.1177/1758835920913426, http://journals.sagepub.com/doi/full-xml/10.1177/1758835920913426, http://journals.sagepub.com/doi/pdf/10.1177/1758835920913426
Annals of Oncology10.1093/annonc/mdx371.050201728v317-v318A Phase (Ph) 1 dose finding study of X4P-001 (an oral CXCR4 inhibitor) and axitinib in patients with advanced renal cell carcinoma (RCC)D.F. McDermott, R.W. Joseph, T. Ho, U. Vaishampayan, S. Ali, M. Matrana, R. Alter, J. Edenfield, S. Blanchette, L. Gan, M.B. Atkinshttps://api.elsevier.com/content/article/PII:S0923753420381692?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753420381692?httpAccept=text/plain, http://academic.oup.com/annonc/article-pdf/28/suppl_5/mdx371.050/19939794/mdx371.050.pdf
Alimentary Pharmacology & Therapeutics10.1111/j.1365-2036.2010.04404.x2010326763-768Pilot study: rapamycin in advanced hepatocellular carcinomaM. Schöniger-Hekele, C. Müllerhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1365-2036.2010.04404.x, http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2036.2010.04404.x/fullpdf
Integrative Cancer Therapies10.1177/1534735413490798201313146-53A Phase I Dose-Finding Study of Silybin Phosphatidylcholine (Milk Thistle) in Patients With Advanced Hepatocellular CarcinomaAbby B. Siegel, Rupa Narayan, Rosa Rodriguez, Abhishek Goyal, Judith S. Jacobson, DrPH, Kara Kelly, Elena Ladas, Paul J. Lunghofer, Ryan J. Hansen, Daniel L. Gustafson, Thomas W. Flaig, Wei Yann Tsai, David P. H. Wu, Valerie Lee, Heather Greenleehttp://journals.sagepub.com/doi/pdf/10.1177/1534735413490798, http://journals.sagepub.com/doi/full-xml/10.1177/1534735413490798, http://journals.sagepub.com/doi/pdf/10.1177/1534735413490798
European Urology10.1016/j.eururo.2018.12.0182019754697-698Re: Preliminary Results for Avelumab Plus Axitinib as First-Line Therapy in Patients with Advanced Clear-cell Renal-cell Carcinoma (JAVELIN Renal 100): An Open-label, Dose-finding and Dose-expansion, Phase 1b TrialViktor Grünwald, Boris Hadaschikhttps://api.elsevier.com/content/article/PII:S0302283818310236?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0302283818310236?httpAccept=text/plain